Tuberculin Skin Test (TST) Segment to Dominate APAC Latent TB Detection Market During 2020–2027                   

According to a new market research study on “APAC Latent TB Detection Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Test and End User” is expected to reach US$ 321.81 million by 2027 from US$ 214.68 million in 2020. The market is estimated to grow at a CAGR of 6.0% from 2020 to 2027. The report provides trends prevailing in the APAC latent TB detection market along with the drivers and restraints pertaining to the market growth. Burgeoning advancements in tuberculosis diagnosis and advent of market in emerging economies are the major factor driving the growth of the APAC latent TB detection market. However, emergence of multidrug resistant tuberculosis (MDR-TB) hinders the growth of APAC latent TB detection market.          

In case of COVID-19, APAC is highly affected specially India. The COVID-19 pandemic has put a major strain on the health systems of many countries around the world and may have negatively affected the delivery of TB services to vulnerable populations. The COVID-19 pandemic threatens to reverse progress in reducing the burden of TB infection in the region. The global number of TB deaths could increase by around 0.2–0.4 million in 2020, if health services are remained disrupted. India, Indonesia, the Philippines, and South Africa account for 44% of global TB cases, and large drops were reported in number of people diagnosed with TB between January and June 2020 due to interrupted healthcare services. The economic impact of the pandemic is predicted to worsen two of the key determinants of TB incidence: GDP per capita and undernutrition. Apart from this, lack of detection in TB cases due to lack of resources is negatively impacting the growth of the market. Many countries have reported the use of GeneXpert machines for COVID-19 testing instead of TB diagnosis, reassignment of staff in national TB programs to COVID-19 related duties and reallocation of budgets are further worsening the situation. In order to bring back the progress made in recent years, it is important to provide additional resources to reduce the number of unknown people with TB.

The APAC latent TB detection market has been segmented into the test, end user, and country. Based on test, the market has been segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA). The tuberculin skin test (TST) segment dominated the APAC latent TB detection market in 2019 and interferon gamma released assay (IGRA) segment is expected to be fastest growing during forecast period. Based on end user, the market has been segmented into the hospitals, diagnostic centers, laboratories, and others. The hospitals segment dominated the APAC latent TB detection market in 2019 and same segment is expected to be fastest growing during forecast period. Based on country, the market has been segmented into China, India, Japan, South Korea, Australia, and rest of APAC.  

Abbott; ARKRAY, Inc.; BD; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Lionex GmbH; Oxford Immunotec Ltd; QIAGEN; and Serum Institute of India Pvt. Ltd. are among the leading companies in the APAC latent TB detection market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, The Oxford Immunotec Ltd has has launched CE-marked T-Cell Select kit in Europe. This will simplify workflow, improve throughput, reduce labor costs in performing the T-SPOT.TB test).                    

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com